Asset Purchase Agreement Dated as of December 7, 2019Asset Purchase Agreement • December 30th, 2019 • XBiotech Inc. • Pharmaceutical preparations • New York
This Asset Purchase Agreement (this “Agreement”) dated as of December 7, 2019 is entered into between Janssen Biotech, Inc., a Pennsylvania corporation (“Buyer”), and XBiotech Inc., a corporation existing under the laws of the Province of British Columbia (“Seller”). Buyer and Seller are sometimes individually referred to herein as a “Party” and are sometimes collectively referred to herein as the “Parties”. Certain capitalized terms used herein have the meanings ascribed to them in Section 1.1.
CLINICAL MANUFACTURING agreement By and between XBiotech USA, Inc. And JANSSEN RESEARCH & DEVELOPMENT LLCClinical Manufacturing Agreement • December 30th, 2019 • XBiotech Inc. • Pharmaceutical preparations • New York
This CLINICAL MANUFACTURING AGREEMENT (this “Agreement”) is entered into as of December 30, 2019 (the “CMA Effective Date”), by and between JANSSEN RESEARCH & DEVELOPMENT LLC, a Pennsylvania corporation, having its principal place of business at 800/850 Ridgeview Drive, Horsham, PA 19044 (hereinafter “Company”), and XBIOTECH USA, INC., a Delaware corporation, having its principal place of business at 5217 Winnebago Lane, Austin, TX 78744 (“SUPPLIER”). Company and SUPPLIER are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
ContractTransition Services Agreement • December 30th, 2019 • XBiotech Inc. • Pharmaceutical preparations • New York
[*****] Text omitted for confidential treatment. The redacted information has been excluded because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.
ContractAgreement • December 30th, 2019 • XBiotech Inc. • Pharmaceutical preparations • New York
[*****] Text omitted for confidential treatment. The redacted information has been excluded because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.
